Briacell Therapeutics CORP

BriaPro Therapeutics reports Q3 2026 financial results, highlighting the acquisition of sCD80 license rights and ongoing pre-clinical development.

BriaPro Therapeutics Corp. filed its unaudited interim financial statements for the period ended January 31, 2026, reporting increased losses and announcing the acquisition of an exclusive license for Soluble CD80 (sCD80) for cancer treatment, alongside a $3 million credit facility from BriaCell.

BriaCell Therapeutics Corp. successfully closed a public offering raising approximately $30 million in gross proceeds through the sale of units comprising common shares and warrants.

BriaPro Therapeutics Corp., a BriaCell subsidiary, reported significantly increased R&D expenses and operating losses for Q3 2025, highlighting its critical dependence on future financing to advance its pre-clinical oncology programs.

BriaPro Therapeutics, a BriaCell subsidiary, reported increased losses for the year ended July 31, 2025, while advancing its pre-clinical immuno-oncology programs, facing significant going concern doubts.

BriaCell Therapeutics Corp. announced a 1-for-10 reverse stock split to ensure continued compliance with Nasdaq Capital Market listing requirements.

BriaCell Therapeutics Corp. reported increased operating expenses and a wider net loss for the third quarter of fiscal year 2026, driven by significant investments in research and development for its immunotherapy candidates.

BriaCell Therapeutics reports increased net loss and significant cash burn, raising substantial doubt about its ability to continue as a going concern, despite advancing its oncology pipeline.

BriaCell Therapeutics Corp. reported a substantial increase in cash and a swing to positive working capital driven by multiple equity offerings, while continuing to advance its Bria-IMT and Bria-OTS immunotherapy programs for metastatic breast cancer despite widening net losses.

BriaCell Therapeutics Corp. announces its financial results for the quarter ended January 31, 2025, alongside updates on its clinical trials and recent financial activities, including multiple offerings and a reverse stock split.

BriaCell Therapeutics Corp. reported its financial results for the first quarter of fiscal year 2025, showing a net loss but also highlighting advancements in its pivotal Phase 3 breast cancer trial and recent capital raises.

BriaCell Therapeutics reported its Q3 2024 financial results, showing a net profit due to a significant decrease in warrant liability, while also detailing progress in its clinical trials and a recent capital raise.

BriaCell Therapeutics Corp. reported a significantly increased net loss for fiscal year 2025, primarily due to warrant revaluation, while advancing its lead immunotherapy candidates in breast and prostate cancer trials.

BriaCell Therapeutics Corp. released its annual report for the fiscal year ended July 31, 2024, detailing financial results and clinical advancements in its immunotherapy programs.

Marc Lustig, a director of BriaCell Therapeutics, indirectly acquired 902,935 common shares and warrants through L5 Capital Inc. in a recent transaction.

BriaCell Therapeutics Corp. announces its Annual General and Special Meeting for March 5, 2026, to address auditor appointment, director elections, and re-approval of its equity incentive plan.

BriaCell Therapeutics Corp. has rescheduled its 2025 Annual General Meeting of Shareholders to February 5, 2025, due to postal service disruptions and to allow more time for proxy solicitation.

BriaCell Therapeutics Corp. has scheduled its annual general meeting for January 23, 2025, to address key corporate matters including the appointment of auditors and the election of directors.

BriaCell Therapeutics Corp. has filed an S-1MEF registration statement to offer up to $11.56 million in common units, pre-funded units, and associated warrants.

BriaCell Therapeutics Corp. files an S-1 registration statement for a best-efforts public offering of up to $25 million in common and pre-funded units to fund working capital and advance business objectives.

BriaCell Therapeutics Corp. has filed an S-1/A registration statement for a public offering of up to 6,825,938 common and pre-funded units, while reporting strong clinical data for its Bria-IMT and Bria-OTS immunotherapies in metastatic breast cancer.

BriaCell Therapeutics Corp. filed an S-1/A registration statement to offer up to 6,825,938 common units and pre-funded units, aiming to raise approximately $18.04 million to advance its clinical-stage cancer immunotherapies, Bria-IMT and Bria-OTS, which have shown promising survival and response rates in metastatic breast cancer.

BriaCell Therapeutics Corp. has filed an S-1 registration statement for a public offering of up to 6.8 million units to fund ongoing operations and advance its clinical-stage immunotherapy programs, following a series of positive clinical data readouts for its Bria-IMT and Bria-OTS candidates in metastatic breast cancer.

BriaCell Therapeutics Corp. is registering additional securities for a proposed maximum aggregate offering price not to exceed $5,318,750.

Citadel and its affiliates, including Kenneth Griffin, have reported a beneficial ownership of 9.99% in BriaCell Therapeutics Corp. common shares.

CVI Investments, Inc. and Heights Capital Management, Inc. have disclosed a 4.9% beneficial ownership stake in BriaCell Therapeutics Corp., primarily through warrants.

An individual investor, Jeremy Myung Jae Plambeck, has filed a Schedule 13G disclosing beneficial ownership of BriaCell Therapeutics Corp. securities, including common shares, warrants, and rights, totaling 13,638.61 common shares, which the filing states represents 100% of the '13G' class of securities.

Iroquois Capital Management, Richard Abbe, and Kimberly Page have disclosed beneficial ownership of BriaCell Therapeutics Corp. common shares, with Richard Abbe holding a 9.1% stake.

Heights Capital Management, acting as investment manager for CVI Investments, Inc., has disclosed a 5.7% beneficial ownership stake in BriaCell Therapeutics Corp., holding 1,000,000 common shares.

CVI Investments, Inc. and Heights Capital Management, Inc. have jointly disclosed a beneficial ownership of 4.9% of BriaCell Therapeutics Corp.'s common shares, primarily through warrants.